MedPath

DANA-FARBER CANCER INSTITUTE

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
-
Website
http://www.dana-farber.org/

High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma

Not Applicable
Terminated
Conditions
Breast Cancer
First Posted Date
2005-09-14
Last Posted Date
2007-12-21
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
15
Registration Number
NCT00165581
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease

Completed
Conditions
Breast Cancer
Hodgkin's Disease
First Posted Date
2005-09-14
Last Posted Date
2019-05-02
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
148
Registration Number
NCT00165412
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Tangential Radiation Therapy Without Axillary Dissection in Breast Cancer

Phase 2
Completed
Conditions
Early-Stage Breast Cancer
First Posted Date
2005-09-14
Last Posted Date
2017-06-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
100
Registration Number
NCT00165243
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

A-protein Levels in Adult and Pediatric Brain Tumor Patients

Completed
Conditions
Malignant Childhood Central Nervous System Neoplasm
Interventions
Other: A PROTEIN level
First Posted Date
2005-09-14
Last Posted Date
2016-11-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
54
Registration Number
NCT00165542
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institite, Boston, Massachusetts, United States

Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate

Phase 2
Terminated
Conditions
Pleural Mesothelioma
Malignant Pleural Mesothelioma
Interventions
Drug: Cisplatin
Drug: Sodium Thiosulfate
Drug: ALIMTA
First Posted Date
2005-09-14
Last Posted Date
2016-09-09
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
16
Registration Number
NCT00165503
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cardiac Screening in Survivors of Hodgkin's Disease Treated With Mediastinal Irradiation

Not Applicable
Active, not recruiting
Conditions
Hodgkin's Disease
Interventions
Procedure: Echo/Stress Echo
First Posted Date
2005-09-14
Last Posted Date
2024-07-03
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
210
Registration Number
NCT00165425
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Brigham and Women's Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Sildenafil Citrate in Waldenstrom's Macroglobulinemia

Phase 2
Completed
Conditions
Waldenstrom's Macroglobulinemia
First Posted Date
2005-09-14
Last Posted Date
2011-06-27
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
30
Registration Number
NCT00165295
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1
Completed
Conditions
Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Multiple Myeloma
Interventions
Drug: Bortezomib
Drug: CC-5013
First Posted Date
2005-09-12
Last Posted Date
2016-01-25
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
58
Registration Number
NCT00153933
Locations
๐Ÿ‡บ๐Ÿ‡ธ

H. Lee Moffitt Cancer Center, Tampa, Florida, United States

๐Ÿ‡บ๐Ÿ‡ธ

Winship Cancer Center, Atlanta, Georgia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
First Posted Date
2005-09-12
Last Posted Date
2013-02-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
40
Registration Number
NCT00153907
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2005-09-12
Last Posted Date
2019-06-11
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
66
Registration Number
NCT00153920
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Emory Winship Cancer Institute, Atlanta, Georgia, United States

and more 3 locations
ยฉ Copyright 2025. All Rights Reserved by MedPath